<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577057</url>
  </required_header>
  <id_info>
    <org_study_id>HKEC-2006-120</org_study_id>
    <secondary_id>HARECCTR0500062</secondary_id>
    <secondary_id>NPC-0501</secondary_id>
    <nct_id>NCT00577057</nct_id>
  </id_info>
  <brief_title>Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer</brief_title>
  <official_title>Randomized Trial to Evaluate the Therapeutic Gain by Changing the Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and the Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hong Kong Nasopharyngeal Cancer Study Group Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      The objectives of this clinical study are threefold:

        1. To compare the benefits in cancer control and survival obtained from adding
           induction-concurrent chemotherapy to radiation with those from adding
           concurrent-adjuvant chemotherapy to radiation.

        2. To test whether replacing fluorouracil with Xeloda in combining with cisplatin (PF or
           PX, respectively) in the chemotherapy plan will maintain or improve further the
           chemotherapy benefits while reducing the duration of hospital stay.

        3. To see if accelerated fractionation radiotherapy can improve the outcome of patients as
           compared with conventional fractionation radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5-year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall / Locoregional / Distant Failure Free Rate</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy and RT toxicity</measure>
    <time_frame>within 90 day from commencement of RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Toxicity</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">798</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Radiotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Accelerated Radiotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven nasopharyngeal carcinoma

          -  Non-keratinizing or undifferentiated type Stage III-IVB (by AJCC/UICC 6th edition)

          -  Essential staging investigations: CT or MRI of nasopharyngeal region Chest x-ray (or
             CT thorax)

          -  Liver function test, alkaline phosphatase Liver and bone scan if alkaline phosphatase
             exceeds the institutional upper limit of normal, or if clinically indicated.

          -  Liver scan if SGOT exceeds the institutional upper limit of normal

          -  Adequate marrow: WBC &gt; 4 and platelet &gt; 100

          -  Adequate renal function: creatinine clearance &gt; 60 ml/min.

          -  Satisfactory performance status: &gt; 2 by ECOG System.

        Exclusion Criteria:

          -  WHO Type I squamous cell carcinoma or adenocarcinoma

          -  Age &gt; 70

          -  Treatment with palliative intent (including those with tumor extent mandating the use
             of AP opposing facio-cervical field technique)

          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer,
             in-situ cervical cancer, or other cancer for which the patient has been disease-free
             for five years.

          -  Pregnancy or lactation (consider pregnancy test in women of child-bearing age and
             emphasize effective contraception during the treatment period).

          -  History of previous RT (except for non-melanomatous skin cancers outside intended RT
             treatment volume).

          -  Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Anne WM Lee, Cos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Oncology, Pamela Youde Nethersole Eastern Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne WM Lee, Cos</last_name>
    <phone>(852) 2595 4173</phone>
    <email>awmlee@ha.org.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ashley Cheng, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roger Ngan, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dora Kwong, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stewart Y Tung, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ekg.org.hk/HAREC-CTR/RegistryDisplay2.jsp?HARECID=HARECCTR0500062</url>
    <description>HAREC Clinical Trial Registry</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <last_update_submitted>August 21, 2013</last_update_submitted>
  <last_update_submitted_qc>August 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2013</last_update_posted>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Stage III - IVB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

